Floatz logo

64cu-dota-ae105

Urinary Bladder Cancer

Rigshospitalet, DenmarkradiopharmaceuticalEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Urinary Bladder Cancer cohort.

Asset / SponsorPhaseRating
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2BB
Atezolizumab
National Cancer Institute (NCI)
Phase 2BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 2BB
Carboplatin
Iambic Therapeutics, Inc
Phase 2BB
TRASTUZUMAB
Iambic Therapeutics, Inc
Phase 2BB

View all 45 →

Same molecule, other indications

64cu-dota-ae105 is also rated in:

prostate cancerDormant
CCC
Indicative ·
50 / 100
View asset →
breast cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →